Paul Ashton

Company: Inflammasome Therapeutics

Job title: Chief Executive Officer

Seminars:

Advancing Implant Technologies to Extend Durability, Reduce Patient Burden & Support Long-Term Treatment of Dry AMD 2:30 pm

Exploring how implantable drug delivery systems are engineered to provide sustained, controlled release of therapeutics directly to retinal tissues Evaluating delivery platform considerations for small molecule and biologic therapies, and how disease stage and progression patterns influence implant design and treatment duration Reviewing ongoing trial investigating implant-based delivery approach; insights into trial design, patient recruitment challenges, and early safety…Read more

day: Day1